New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
17:02 EDTGHDXGenomic Health announces data reinforcing robustness of Oncotype DX
Genomic Health presented positive results reinforcing the robustness of the Oncotype DX prostate cancer test's development as a predictor of prostate cancer aggressiveness. A sub-analysis of a large Oncotype DX Genomic Prostate Score, or GPS, development study suggests that GPS predicts time to clinical progression regardless of the treatment received following surgery. This exploratory analysis from one of the original development studies looked at a subset of 185 prostate cancer patients who experienced biochemical recurrence after surgery. These patients were analyzed in three subgroups based on treatment received at time of biochemical recurrence: men who did not receive additional treatment, men who received hormonal therapy and men who received radiation therapy. Results showed that the Oncotype DX Genomic Prostate Score was predictive of clinical recurrence for all patients, regardless of the type of treatment patients received. For each therapy subgroup, different biological pathways within the GPS were most highly associated with patient outcome.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
21:23 EDTGHDXGenomic Health management to meet with William Blair
Subscribe for More Information
February 26, 2015
12:40 EDTGHDXGenomic Health management to meet with Piper Jaffray
Meeting to be held in New York on March 4 hosted by Piper Jaffray.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use